Abstract
VIC-1911 (formerly TAS-119) is a next-generation, ATP-competitive aurora kinase A (AURKA) inhibitor with a favorable biosafety profile. However, it has not been evaluated in prostate cancer (PCa), wherein AURKA is highly expressed in advanced stages and represents a critical therapeutic target. Here, we demonstrate that VIC-1911 potently inhibits AURKA activity with high selectivity over AURKB/C across diverse PCa cell lines. Treatment with VIC-1911, even at nanomolar concentrations, substantially inhibits the growth of both androgen receptor–positive (AR-positive) and AR-negative PCa cells. VIC-1911 triggers mitotic failure, induces DNA double-strand breaks (DSBs), and activates the p53 pathway, halting cell division and inducing cell death. Notably, VIC-1911 showed synergistic effects in inhibiting PCa cell growth in vitro and xenograft tumor growth in vivo with poly (ADP-ribose) polymerase inhibitors, which have proven effective in PCa with a deficiency in homologous recombination (HR) repair. Mechanistically, VIC-1911 disabled HR-mediated repair of DSBs in otherwise HR-proficient PCa cells, leading to a “BRCAness” phenotype and pronounced accumulation of DNA damage and mitotic catastrophe. In summary, our study uncovers what we believe is a novel mechanism to induce functional BRCAness through mitotic arrest and highlights VIC-1911 as a promising therapeutic agent for advanced PCa, either as a single agent or in combination, sensitizing HR-proficient tumors to PARP inhibitors.
Authors
Galina Gritsina, Sandip Kumar Rath, Hongshun Shi, Qi Chu, Wanqing Xie, Que Thanh Thanh Nguyen, Sambhavi Senthil, Thomas J. Myers, Mehmet A. Bilen, Sarah E. Fenton, Maha Hussain, David S. Yu, Jonathan C Zhao, Jindan Yu
Figure 2
VIC-1911 inhibits cell growth and activates the P53 pathway.
